Prognostic significance of 14-3-3σ expression in oral squamous cell carcinoma (OSCC)

Oral Oncology

Volumn 45, Issue 2, 2009, Pages 127-134

  Laimer, Klaus ^a   Blassnig, Nicola ^a   Spizzo, Gilbert ^a   Kloss, Frank ^a   Rasse, Michael ^a   Obrist, Peter ^a   Schäfer, Georg ^b   Perathoner, Alexander ^a   Margreiter, Raimund ^a   Amberger, Albert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Saint Vincent Hospital Zams   (Austria)

Author keywords

14 3 3 ; Chemotherapy; Kaplan Meier analysis; OSCC; p53; Prognostic marker

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; STRATIFIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIVARIATE ANALYSIS; ORAL SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VALIDATION STUDY;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58549113770     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.04.006     Document Type: Article

References (35)

1. Muir C., and Weiland L. Upper aerodigestive tract cancers. Cancer 75 (1995) 147-153
2. Sasaki T., Moles D.R., Imai Y., and Speight P.M. Clinico-pathological features of squamous cell carcinoma of the oral cavity in patients <40 years of age. J Oral Pathol Med 34 (2005) 129-133
3. Thomas G.R., Nadiminti H., and Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86 (2005) 347-363
4. Miller C.S., Henry R.G., and Rayens M.K. Disparities in risk of and survival from oropharyngeal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 570-575
5. Wolff D., Hassfeld S., and Hofele C. Influence of marginal and segmental mandibular resection on the survival rate in patients with squamous cell carcinoma of the inferior parts of the oral cavity. J Craniomaxillofac Surg 32 (2004) 318-323
6. Dougherty M.K., and Morrison D.K. Unlocking the code of 14-3-3. J Cell Sci 117 (2004) 1875-1884
7. Fu H., Subramanian R.R., and Masters S.C. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40 (2000) 617-647
8. MacKintosh C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J 381 (2004) 329-342
9. Muslin A.J., Tanner J.W., Allen P.M., and Shaw A.S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84 (1996) 889-897
10. Yaffe M.B., Rittinger K., Volinia S., Caron P.R., Aitken A., Leffers H., et al. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91 (1997) 961-971
11. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 3 (2003) 931-943
12. Ferguson A.T., Evron E., Umbricht C.B., Pandita T.K., Chan T.A., Hermeking H., et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97 (2000) 6049-6054
13. Iwata N., Yamamoto H., Sasaki S., Itoh F., Suzuki H., Kikuchi T., et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19 (2000) 5298-5302
14. Osada H., Tatematsu Y., Yatabe Y., Nakagawa T., Konishi H., Harano T., et al. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 21 (2002) 2418-2424
15. Cheng L., Pan C.X., Zhang J.T., Zhang S., Kinch M.S., Li L., et al. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res 10 (2004) 3064-3068
16. Ide M., Nakajima T., Asao T., and Kuwano H. Inactivation of 14-3-3sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front. Cancer Lett 207 (2004) 241-249
17. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H., and Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60 (2000) 4353-4357
18. Perathoner A., Pirkebner D., Brandacher G., Spizzo G., Stadlmann S., Obrist P., et al. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11 (2005) 3274-3279
19. Guweidhi A., Kleeff J., Giese N., Fitori J.E., Ketterer K., Giese T., et al. Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 25 (2004) 1575-1585
20. Hustinx S.R., Fukushima N., Zahurak M.L., Riall T.S., Maitra A., Brosens L., et al. Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol Ther 4 (2005) 596-601
21. Sato N., Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., Iacobuzio-Donahue C.A., et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63 (2003) 4158-4166
22. Gasco M., Bell A.K., Heath V., Sullivan A., Smith P., Hiller L., et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 62 (2002) 2072-2076
23. Chen J., He Q.Y., Yuen A.P., and Chiu J.F. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 4 (2004) 2465-2475
24. Lo W.Y., Tsai M.H., Tsai Y., Hua C.H., Tsai F.J., Huang S.Y., et al. Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta (2006)
25. Roesch-Ely M., Nees M., Karsai S., Ruess A., Bogumil R., Warnken U., et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26 (2007) 54-64
26. Erovic B.M., Pelzmann M., Grasl M.C., Pammer J., Kornek G., Brannath W., et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res 11 (2005) 8632-8636
27. Samuel T., Weber H.O., Rauch P., Verdoodt B., Eppel J.T., McShea A., et al. The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem 276 (2001) 45201-45206
28. Zhang Y., Karas M., Zhao H., Yakar S., and LeRoith D. 14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation. J Biol Chem 279 (2004) 34353-34360
29. Liu Y., Liu H., Han B., and Zhang J.T. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66 (2006) 3248-3255
30. Han B., Xie H., Chen Q., and Zhang J.T. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}. Mol Cancer Ther 5 (2006) 903-912
31. Qi W., and Martinez J.D. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 160 (2003) 217-223
32. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1 (1997) 3-11
33. Riethdorf S., Friedrich R.E., Ostwald C., Barten M., Gogacz P., Gundlach K.K., et al. p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long-term follow-up study. J Oral Pathol Med 26 (1997) 315-321
34. Gapany M., Pavelic Z.P., Gapany S.R., Pavelic L., Li Y.G., Craven J.M., et al. Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 17 (1993) 379-386
35. Raybaud-Diogene H., Tetu B., Morency R., Fortin A., and Monteil R.A. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 32B (1996) 143-149